新聞稿 | HIPRA

who we are

新聞稿

01/17/2023 - 14:29

HIPRA’s COVID-19 vaccine trial in people with immunocompromising conditions was launched in Turkey

人類

11/07/2022 - 17:20

HIPRA starts a clinical trial to study its vaccine against COVID-19 as a 4th dose

人類

07/19/2022 - 10:14

HIPRA’s COVID-19 vaccine induces a good neutralising antibody response against the BA.2, BA.4 and BA.5 subvariants of Omicron

人類

05/18/2022 - 10:13

HIPRA initiates the first Phase III clinical trial of Covid-19 vaccine in immunocompromised people

人類

03/29/2022 - 14:02

EMA starts rolling review of Covid-19 HIPRA’s vaccine

人類

03/16/2022 - 08:45

GoodGut and Vall d'Hebron Barcelona Hospital are studying the implementation of the first non-invasive diagnostic test to detect Irritable Bowel Syndrome

人類